Bevacizumab biosimilar – Mvasi® (ABP215)


MUDr. Lukáš Chlachula

Komplexní onkologické centrum, Nemocnice Nový Jičín



Monoclonal antibodies to various structures represent an important milestone in oncological treatment and form a clearly established group of anticancer therapy. However, we find their application in practically all fields of medicine. Bevacizumab is one of the first mass-established in oncology practice. However, there are also biosimilar drugs that are not identical generic copies of the reference drugs, but nevertheless have the same properties as the reference product. Mvasi® is the first FDA and EMA approved biosimilar for bevacizumab to treat a large group of cancers. Through a specific approval process (totality of evidence, TOE), it demonstrated the same properties, including efficacy, as the reference product (bevacizumab).


Key words

Mvasi®, bevacizumab, biosimilar drugs, VEGF-A



The full article is only available to subscribers

Become a regular subscriber to our Oncological Review...